Absci Corporation

ABSI

US00091E1091

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 20:00:28 12/02/2026 GMT			5-day change	1st Jan Change
2.435 ^USD	-6.35%		-3.36%	-29.94%

01-15	Absci Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 03:45 PM
01-08	Morgan Stanley Downgrades Absci to Equal Weight From Overweight, Adjusts PT to $4.32 From $5.80	MT

Sector Update: Health Care Stocks Rise Premarket Wednesday

Published on 01/08/2025 at 02:19 pm GMT - Modified on 01/08/2025 at 02:20 pm GMT

MT Newswires

Latest news about Absci Corporation

01-15	Absci Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 03:45 PM
01-08	Morgan Stanley Downgrades Absci to Equal Weight From Overweight, Adjusts PT to $4.32 From $5.80	MT
12-22	Absci Corporation(NasdaqGS:ABSI) added to S&P Biotechnology Select Industry Index	CI
12-11	Absci Corporation - Special Call
12-11	Absci Corporation Unveils New Preclinical Data for Abs-201	CI
12-11	Absci Says Preclinical Data Shows ABS-201 Promotes Hair Growth	MT
12-04	Absci Reports First Participant Dosing in Phase 1/2a Androgenetic Alopecia Treatment Study	MT
12-04	Absci Corporation Announces First Participants Dosed in Phase 1/2a Headline? Trial of AI-Designed Antibody ABS-201? for Androgenetic Alopecia	CI
12-04	Absci announces first participants dosed in phase 1/2a headline trial	RE
11-22	Absci Corporation Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 09:30 AM
11-17	Morgan Stanley Trims Price Target on Absci to $5.80 From $5.89, Keeps Overweight Rating	MT
11-13	Absci Corporation, Q3 2025 Earnings Call, Nov 12, 2025
11-12	Absci Q3 net loss widens	RE
11-12	Absci Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
23/10/25	Certain Common Stock of Absci Corporation are subject to a Lock-Up Agreement Ending on 23-OCT-2025.	CI
23/10/25	Certain Stock Options of Absci Corporation are subject to a Lock-Up Agreement Ending on 23-OCT-2025.	CI
23/10/25	Certain Restricted Stock Unit of Absci Corporation are subject to a Lock-Up Agreement Ending on 23-OCT-2025.	CI
15/10/25	Absci Announces Accelerated Initiation of Phase 1/2a Trial	CI
24/09/25	Absci Insider Bought Shares Worth $254,788, According to a Recent SEC Filing	MT
11/09/25	Sector Update: Health Care Stocks Climb Late Afternoon	MT
11/09/25	Sector Update: Health Care	MT
11/09/25	Absci Forms Collaboration With Oracle, AMD to Support AI-Powered Drug Discovery	MT
11/09/25	Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD	CI
11/09/25	Absci accelerates AI-driven drug discovery with Oracle and AMD	RE
08/09/25	Absci Corporation Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-08-2025 03:20 PM

Absci Corporation is a data-first generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. The Companyâ€™s Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, its Integrated Drug Creation platform aims to engineer biologics. It is developing a diversified portfolio of programs with a focus on cytokine biology. It has three wholly owned internal pipeline programs focusing on cytokine biology, as well as several other undisclosed pipeline programs under evaluation. Its wholly owned pipeline programs include ABS-101, ABS-201, and ABS-301. The Companyâ€™s other pipeline programs include ABS-501 and additional drug creation programs.

Employees

157

Sector

Biotechnology & Medical Research

Calendar

03-23 - Q4 2025 Earnings Release (Projected)

More about the company